BRAF mutant gastrointestinal stromal tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance

G. S. Falchook, J. C. Trent, M. C. Heinrich, C. Beadling, J. Patterson, C. C. Bastida, S. C. Blackman, R. Kurzrock

Research output: Contribution to journal › Article › peer-review

139 Scopus citations

Fingerprint

Dive into the research topics of 'BRAF mutant gastrointestinal stromal tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science